Verrica Pharmaceuticals - VRCA Stock Forecast, Price & News

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on VRCA shares. Royal Bank of Canada cut Verrica Pharmaceuticals from an "outperform" rating to a "sector perform" rating and reduced their price target for the stock from $16.00 to $4.00 in a report on Wednesday, May 25th. Needham & Company LLC cut Verrica Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Wednesday, May 25th. Finally, HC Wainwright reiterated a "buy" rating and issued a $12.00 price objective on shares of Verrica Pharmaceuticals in a report on Wednesday, June 29th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $14.80.

Verrica Pharmaceuticals Stock Up 1.7 %

Verrica Pharmaceuticals stock traded up $0.07 during mid-day trading on Monday, reaching $4.11. 553 shares of the stock traded hands, compared to its average volume of 276,484. The business's 50-day moving average is $2.80 and its 200-day moving average is $5.61. Verrica Pharmaceuticals has a 12-month low of $1.77 and a 12-month high of $14.79.

Insider Buying and Selling at Verrica Pharmaceuticals

In related news, major shareholder Perceptive Advisors Llc purchased 1,428,571 shares of the company's stock in a transaction on Tuesday, July 5th. The shares were bought at an average cost of $2.10 per share, for a total transaction of $2,999,999.10. Following the transaction, the insider now owns 5,038,983 shares of the company's stock, valued at $10,581,864.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director John A. Stalfort III bought 238,095 shares of the firm's stock in a transaction on Tuesday, July 5th. The stock was acquired at an average cost of $2.10 per share, with a total value of $499,999.50. Following the transaction, the director now directly owns 700,205 shares in the company, valued at approximately $1,470,430.50. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Perceptive Advisors Llc purchased 1,428,571 shares of the firm's stock in a transaction on Tuesday, July 5th. The shares were purchased at an average price of $2.10 per share, for a total transaction of $2,999,999.10. Following the completion of the purchase, the insider now directly owns 5,038,983 shares of the company's stock, valued at $10,581,864.30. The disclosure for this purchase can be found here. Insiders purchased 1,703,689 shares of company stock worth $3,587,497 over the last 90 days. Corporate insiders own 43.50% of the company's stock.